Research programme: IRAK-4 inhibitors - Aurigene/Curis

Drug Profile

Research programme: IRAK-4 inhibitors - Aurigene/Curis

Alternative Names: Interleukin-1 receptor-associated kinase 4 inhibitors - Aurigene/Curis; IRAK-4 inhibitors; IRAK4 kinase inhibitors - Aurigene/Curis

Latest Information Update: 13 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Discovery Technologies; Curis
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Inflammation

Most Recent Events

  • 29 Feb 2016 Curis plans a phase I trial for Haematological malignancies in USA (Curis, Form 10-K, February 2016)
  • 07 Oct 2015 Curis exercises its option to exclusively license small molecule antagonists of Interleukin-1 receptor-associated kinase 4 (IRAK4)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top